Pathogenesis and therapeutic targeting of aberrant MYC expression in haematological cancers
- 24 November 2017
- journal article
- review article
- Published by Wiley in British Journal of Haematology
- Vol. 179 (5) , 724-738
Abstract
Summary: Identifying and therapeutically targeting cancer cell liabilities is of utmost importance in order to improve the treatment of patients with malignancies of poor prognosis. The MYC family genes (MYC, MYCN and MYCL) are among the most deregulated proto‐oncogenes in human cancer. Aberrant MYC expression is frequently associated with poor prognosis. Although many aspects of MYC‐mediated tumour biology are well characterized, there are currently no effective means for targeting MYC in a specific manner that have been established for clinical use. This review first discusses the role of MYC in the pathogenesis of haematopoietic malignancies, and secondly summarizes how insight into MYC functions could be translated into therapeutic approaches. In particular, we will address the possibilities of taking advantage of MYC‐induced cancer cell vulnerabilities that could be exploited in terms of synthetic lethal interactions.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft
- Deutsche Krebshilfe
- Horizon 2020 Framework Programme
- Knut och Alice Wallenbergs Stiftelse
- Erling-Perssons Stiftelse
- Sahlgrenska Universitetssjukhuset
This publication has 157 references indexed in Scilit:
- Synthetic lethal metabolic targeting of cellular senescence in cancer therapyNature, 2013
- The Transcription Factor Myc Controls Metabolic Reprogramming upon T Lymphocyte ActivationImmunity, 2011
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-MycCell, 2011
- Regulation of chromatin by histone modificationsCell Research, 2011
- CD4+ T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene InactivationCancer Cell, 2010
- Selective inhibition of BET bromodomainsNature, 2010
- Origin and function of ubiquitin-like proteinsNature, 2009
- IRF4 addiction in multiple myelomaNature, 2008
- AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center MalignanciesCancer Cell, 2008
- The Concept of Synthetic Lethality in the Context of Anticancer TherapyNature Reviews Cancer, 2005